Figure 2.

Adjusted risk of discontinuing therapy stratified by reason for discontinuation. The multivariable model was adjusted for age, gender, diagnosis of constipation-predominant irritable bowel syndrome (vs chronic idiopathic constipation), and management of therapy by gastroenterology (vs nongastroenterology). Results are presented as: risk of discontinuation for any reason (a), risk of discontinuation due to intolerance (b), and risk of discontinuation due to insufficient efficacy of therapy (c). Adjusting for covariates, individuals were more likely to discontinue lubiprostone for any reason or due to insufficient efficacy as reported by the patient or provider. Individuals were more likely to discontinue therapy due to intolerance with linaclotide.